BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

$82.88 0.32 (0.39 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$82.88
Today's Range$83.36 - $82.13
52-Week Range$79.50 - $100.51
Volume970,247 shs
Average Volume1.25 million shs
Market Capitalization$14.5 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.


Industry, Sector and Symbol:
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Sector: Biopharmaceuticals
  • Symbol: NASDAQ:BMRN
  • CUSIP: 09061G10
  • Web: www.bmrn.com
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 4.91%
  • Quick Ratio: 3.81%
Sales & Book Value:
  • Annual Sales: $1.11685 billion
  • Price / Sales: 13.03
  • Book Value: $16.02 per share
  • Price / Book: 5.17
Profitability:
  • Trailing EPS: ($0.83)
  • Net Income: ($630,210,000.00)
  • Net Margins: -12.45%
  • Return on Equity: -4.60%
  • Return on Assets: -3.09%
Misc:
  • Employees: 2,293
  • Outstanding Shares: 175,620,000
 

Frequently Asked Questions for BioMarin Pharmaceutical (NASDAQ:BMRN)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its earnings results on Thursday, October, 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.06. The biotechnology company had revenue of $334.18 million for the quarter, compared to analyst estimates of $347.38 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The business's revenue was up 19.4% on a year-over-year basis. During the same period last year, the company posted $0.02 EPS. View BioMarin Pharmaceutical's Earnings History.

When will BioMarin Pharmaceutical make its next earnings announcement?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for BioMarin Pharmaceutical.

Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2017?

22 brokers have issued 12-month price targets for BioMarin Pharmaceutical's shares. Their predictions range from $89.00 to $150.00. On average, they expect BioMarin Pharmaceutical's stock price to reach $113.52 in the next twelve months. View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "BioMarin should continue to see growth in both its orphan disease drugs – Vimizim and Kuvan – in 2017 backed by robust patient growth and penetration. Pipeline development is also on track with a potential approval for pegvaliase in 2018. However, BioMarin has suffered quite a few regulatory setbacks related to its pipeline candidates, Brineura and Kyndrisa. Delayed approvals or development setbacks could have a negative impact on the stock. Also, Naglazyme revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries. Meanwhile, BioMarin is facing generic threat for Kuvan. The earlier-than-expected entry of generics will be a huge blow for the company.  The stock has underperformed the industry in the past six months. Loss estimates have slightly widened ahead of the company’s Q3 earnings result. BioMarin has a positive record of earnings surprises in the recent quarters." (10/16/2017)
  • 2. Cowen and Company analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)
  • 3. Wedbush analysts commented, "The Wedbush View: While we see meaningful clinical, regulatory and commercial progress this year, we remain NEUTRAL on BMRN as we believe the stock is relatively expensive as it consistently trades at the top of peers." (5/8/2017)
  • 4. Jefferies Group LLC analysts commented, "Narrower 1Q GAAP net loss reflects higher revenue & lower OpEx (non- GAAP income of $35M). Next clinical update includes BMN 270 data at ISTH on 7/8-7/13/17." (5/5/2017)
  • 5. J P Morgan Chase & Co analysts commented, "By Lotus Inventory Impacting Margins In Q1, all rev lines came in above expectations. While Med-Surg has been a consistent outperformer of late, CRM upside was another bright spot. The strong growth came against a tough comp. Headline margins were disappointing due to a spate of issues including the Lotus recall (not surprising), Fuse scope losses (somewhat more surprising) and litigation charges (also not surprising). The Lotus and Fuse charges are not expected to recur; excluding these, we view margins as fairly in-line. While the revenue raise positions BSX shares more favorably in our view, we continue to see the potential for risk around Lotus. While we expect strong data at EuroPCR, we wonder if mgmt’s FDA timelines are aggressive as we would think the FDA might ask for meaningful additional clinical work on the new delivery system following the EU recall. We remain positive on BSX’s underlying fundamentals but feel its current P/E valuation is appropriate until Lotus issues are entirely resolved or Symetis closes and sales ramp." (5/1/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:

  • Jean-Jacques Bienaime, Chairman of the Board, Chief Executive Officer (Age 63)
  • Daniel Keith Spiegelman, Chief Financial Officer, Executive Vice President (Age 58)
  • G. Eric Davis, Executive Vice President, General Counsel, Secretary (Age 46)
  • Jeff Robert Ajer, Executive Vice President, Chief Commercial Officer (Age 55)
  • Robert A. Baffi Ph.D., Executive Vice President - Technical Operations (Age 62)
  • Henry J. Fuchs M.D., Executive Vice President and Chief Medical Officer (Age 59)
  • Brian R. Mueller, Group Vice President, Corporate Controller, Chief Accounting Officer (Age 43)
  • Richard A. Meier, Lead Independent Director (Age 57)
  • Willard H. Dere M.D., Independent Director (Age 63)
  • Michael G. Grey, Independent Director

Who owns BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Jennison Associates LLC (7.01%), Manning & Napier Advisors LLC (1.18%), Pictet Asset Management Ltd. (0.65%), TCW Group Inc. (0.61%), Frontier Capital Management Co. LLC (0.43%) and Legal & General Group Plc (0.43%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Who sold BioMarin Pharmaceutical stock? Who is selling BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Neuberger Berman Group LLC, Canada Pension Plan Investment Board, Sectoral Asset Management Inc, Sumitomo Mitsui Trust Holdings Inc., Frontier Capital Management Co. LLC, Manning & Napier Advisors LLC and Great West Life Assurance Co. Can. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Who bought BioMarin Pharmaceutical stock? Who is buying BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including American Century Companies Inc., TCW Group Inc., Pictet Asset Management Ltd., Westfield Capital Management Co. LP, First Trust Advisors LP, WINTON GROUP Ltd, Scout Investments Inc. and Highbridge Capital Management LLC. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy BioMarin Pharmaceutical stock?

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $82.88.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $14.5 billion and generates $1.11685 billion in revenue each year. The biotechnology company earns ($630,210,000.00) in net income (profit) each year or ($0.83) on an earnings per share basis. BioMarin Pharmaceutical employs 2,293 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 105 Digital Dr, NOVATO, CA 94949-8703, United States. The biotechnology company can be reached via phone at +1-415-5066700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  881 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  1,293
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 6 Hold Ratings, 16 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.73)
Consensus Price Target: $113.52 (36.97% upside)

Consensus Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)

Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017WedbushReiterated RatingNeutral$108.00N/AView Rating Details
10/29/2017J P Morgan Chase & CoSet Price TargetBuy$130.00N/AView Rating Details
10/27/2017BMO Capital MarketsBoost Price TargetOutperform$117.00 -> $119.00N/AView Rating Details
10/27/2017Stifel NicolausLower Price TargetBuy$107.00 -> $105.00N/AView Rating Details
10/19/2017SunTrust Banks, Inc.Set Price TargetBuy$115.00N/AView Rating Details
10/19/2017Leerink SwannReiterated RatingOutperform$136.00 -> $142.00N/AView Rating Details
10/19/2017Credit Suisse GroupReiterated RatingOutperform$114.00 -> $124.00N/AView Rating Details
10/6/2017The Goldman Sachs Group, Inc.Reiterated RatingBuy -> Buy$129.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$115.00 -> $117.00N/AView Rating Details
9/26/2017Jefferies Group LLCReiterated RatingBuy$116.00LowView Rating Details
9/21/2017Piper Jaffray CompaniesReiterated RatingBuy$113.00MediumView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$93.00MediumView Rating Details
8/31/2017Citigroup Inc.Initiated CoverageBuy -> Buy$98.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$100.00HighView Rating Details
8/9/2017Deutsche Bank AGReiterated RatingBuy$118.00 -> $119.00LowView Rating Details
8/4/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00HighView Rating Details
7/22/2017Barclays PLCReiterated RatingEqual Weight$105.00 -> $100.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$93.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/10/2017GabelliReiterated RatingBuyN/AView Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/AView Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00N/AView Rating Details
6/20/2016Oppenheimer Holdings, Inc.Reiterated RatingMarket Perform$99.00N/AView Rating Details
1/15/2016Bank of America CorporationReiterated RatingBuy$165.00 -> $135.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for BioMarin Pharmaceutical (NASDAQ:BMRN)

Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Earnings History by Quarter for BioMarin Pharmaceutical (NASDAQ BMRN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
10/26/2017Q3 2017($0.13)($0.07)$347.38 million$334.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.22)($0.21)$311.41 million$317.50 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.30)$0.03$292.58 million$303.70 millionViewListenView Earnings Details
2/23/2017Q416($0.38)($0.53)$296.54 million$300.00 millionViewN/AView Earnings Details
10/27/2016Q316($0.39)($0.13)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.22)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.25)$204.58 million$203.26 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.30)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.42)($0.19)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.50)($0.27)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
2017 EPS Consensus Estimate: ($0.93)
2018 EPS Consensus Estimate: ($0.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.38)($0.22)($0.32)
Q2 20174($0.35)($0.17)($0.26)
Q3 20175($0.27)($0.06)($0.11)
Q4 20175($0.33)($0.12)($0.24)
Q1 20182($0.32)($0.17)($0.25)
Q2 20182($0.19)($0.12)($0.16)
Q3 20183($0.21)($0.10)($0.16)
Q4 20182($0.15)($0.06)($0.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioMarin Pharmaceutical (NASDAQ BMRN)

Insider Ownership Percentage: 1.85%
Institutional Ownership Percentage: 96.89%
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ BMRN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Robert BaffiEVPSell18,415$92.43$1,702,098.45View SEC Filing  
9/22/2017Jeffrey Robert AjerEVPSell3,521$95.00$334,495.00View SEC Filing  
9/15/2017Henry J FuchsInsiderSell15,000$90.50$1,357,500.00View SEC Filing  
9/15/2017V Bryan LawlisDirectorSell3,750$91.26$342,225.00View SEC Filing  
6/23/2017George Eric DavisEVPSell9,844$96.60$950,930.40View SEC Filing  
6/22/2017Brian MuellerSVPSell2,671$100.00$267,100.00View SEC Filing  
6/19/2017Henry J FuchsInsiderSell15,000$90.00$1,350,000.00View SEC Filing  
6/16/2017V Bryan LawlisDirectorSell3,750$90.00$337,500.00View SEC Filing  
6/7/2017Jeffrey Robert AjerEVPSell1,004$89.61$89,968.44View SEC Filing  
6/5/2017George Eric DavisEVPSell9,471$91.04$862,239.84View SEC Filing  
6/5/2017Jean Jacques BienaimeCEOSell10,000$90.13$901,300.00View SEC Filing  
5/24/2017Jean Jacques BienaimeCEOSell5,000$88.38$441,900.00View SEC Filing  
5/17/2017Jean Jacques BienaimeCEOSell5,000$91.73$458,650.00View SEC Filing  
5/8/2017Brian MuellerSVPSell7,482$91.87$687,371.34View SEC Filing  
5/8/2017Jean Jacques BienaimeCEOSell10,000$96.09$960,900.00View SEC Filing  
5/5/2017George Eric DavisEVPSell2,500$100.34$250,850.00View SEC Filing  
5/2/2017Jeffrey Robert AjerEVPSell302$96.74$29,215.48View SEC Filing  
4/27/2017Jean Jacques BienaimeCEOSell5,000$95.72$478,600.00View SEC Filing  
4/25/2017Jean Jacques BienaimeCEOSell5,000$94.00$470,000.00View SEC Filing  
3/29/2017Jeffrey Robert AjerEVPSell3,890$89.15$346,793.50View SEC Filing  
3/16/2017Daniel K SpiegelmanCFOSell1,989$91.96$182,908.44View SEC Filing  
3/16/2017George Eric DavisEVPSell2,238$91.96$205,806.48View SEC Filing  
3/16/2017Jean Jacques BienaimeCEOSell10,000$91.69$916,900.00View SEC Filing  
3/10/2017Jean Jacques BienaimeCEOSell11,000$90.59$996,490.00View SEC Filing  
3/7/2017Jeffrey Robert AjerEVPSell5,000$90.56$452,800.00View SEC Filing  
3/6/2017Daniel K SpiegelmanCFOSell2,303$93.32$214,915.96View SEC Filing  
3/6/2017George Eric DavisEVPSell1,498$93.32$139,793.36View SEC Filing  
3/1/2017Daniel K SpiegelmanCFOSell35,000$94.07$3,292,450.00View SEC Filing  
3/1/2017V Bryan LawlisDirectorSell7,500$95.00$712,500.00View SEC Filing  
2/24/2017Henry J FuchsInsiderSell15,000$87.99$1,319,850.00View SEC Filing  
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.00View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.87View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioMarin Pharmaceutical (NASDAQ:BMRN)

Latest Headlines for BioMarin Pharmaceutical (NASDAQ BMRN)

Source:
DateHeadline
BioMarin Pharmaceutical Inc. (BMRN) Receives Neutral Rating from WedbushBioMarin Pharmaceutical Inc. (BMRN) Receives Neutral Rating from Wedbush
www.americanbankingnews.com - November 15 at 3:38 PM
BioMarin Pharmaceutical is Now Oversold (BMRN) - NasdaqBioMarin Pharmaceutical is Now Oversold (BMRN) - Nasdaq
www.nasdaq.com - November 15 at 3:08 AM
ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 13, 2017ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 12:44 AM
$349.10 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter$349.10 Million in Sales Expected for BioMarin Pharmaceutical Inc. (BMRN) This Quarter
www.americanbankingnews.com - November 8 at 4:30 AM
Earnings Growth Make BioMarin Pharmaceuticals (BMRN) a SellEarnings Growth Make BioMarin Pharmaceuticals (BMRN) a Sell
investorplace.com - November 6 at 9:25 PM
Zacks: Analysts Anticipate BioMarin Pharmaceutical Inc. (BMRN) to Announce -$0.25 Earnings Per ShareZacks: Analysts Anticipate BioMarin Pharmaceutical Inc. (BMRN) to Announce -$0.25 Earnings Per Share
www.americanbankingnews.com - November 6 at 9:22 PM
BioMarin Pharmaceutical Inc. (BMRN) Given Consensus Rating of "Hold" by BrokeragesBioMarin Pharmaceutical Inc. (BMRN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 6 at 6:11 PM
BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017BioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 5:14 PM
ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 3, 2017ETFs with exposure to BioMarin Pharmaceutical, Inc. : November 3, 2017
finance.yahoo.com - November 3 at 5:14 PM
Financial Contrast: BioMarin Pharmaceutical (BMRN) versus Its RivalsFinancial Contrast: BioMarin Pharmaceutical (BMRN) versus Its Rivals
www.americanbankingnews.com - November 2 at 7:22 PM
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth GoalBioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
finance.yahoo.com - November 1 at 5:16 PM
Brokers Issue Forecasts for BioMarin Pharmaceutical Inc.s FY2017 Earnings (BMRN)Brokers Issue Forecasts for BioMarin Pharmaceutical Inc.'s FY2017 Earnings (BMRN)
www.americanbankingnews.com - November 1 at 10:28 AM
BioMarin to Attend Three Upcoming Investor ConferencesBioMarin to Attend Three Upcoming Investor Conferences
finance.yahoo.com - October 31 at 5:45 PM
Q1 2018 Earnings Estimate for BioMarin Pharmaceutical Inc. Issued By SunTrust Banks (BMRN)Q1 2018 Earnings Estimate for BioMarin Pharmaceutical Inc. Issued By SunTrust Banks (BMRN)
www.americanbankingnews.com - October 31 at 11:58 AM
FY2020 Earnings Estimate for BioMarin Pharmaceutical Inc. (BMRN) Issued By GabelliFY2020 Earnings Estimate for BioMarin Pharmaceutical Inc. (BMRN) Issued By Gabelli
www.americanbankingnews.com - October 30 at 11:53 AM
Brokers Set Expectations for BioMarin Pharmaceutical Inc.s Q3 2018 Earnings (BMRN)Brokers Set Expectations for BioMarin Pharmaceutical Inc.'s Q3 2018 Earnings (BMRN)
www.americanbankingnews.com - October 30 at 9:42 AM
BMO Capital Markets Increases BioMarin Pharmaceutical Inc. (BMRN) Price Target to $119.00BMO Capital Markets Increases BioMarin Pharmaceutical Inc. (BMRN) Price Target to $119.00
www.americanbankingnews.com - October 28 at 3:34 PM
BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised - NasdaqBioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised - Nasdaq
www.nasdaq.com - October 28 at 12:01 AM
Edited Transcript of BMRN earnings conference call or presentation 26-Oct-17 8:30pm GMTEdited Transcript of BMRN earnings conference call or presentation 26-Oct-17 8:30pm GMT
finance.yahoo.com - October 27 at 6:59 PM
BioMarin Pharmaceutical Inc. to Post Q3 2017 Earnings of ($0.07) Per Share, Leerink Swann Forecasts (BMRN)BioMarin Pharmaceutical Inc. to Post Q3 2017 Earnings of ($0.07) Per Share, Leerink Swann Forecasts (BMRN)
www.americanbankingnews.com - October 27 at 6:34 AM
BioMarin Pharmaceutical (BMRN) Q3 2017 Results - Earnings Call TranscriptBioMarin Pharmaceutical (BMRN) Q3 2017 Results - Earnings Call Transcript
www.msn.com - October 27 at 2:49 AM
BioMarin Increases 2017 Non-GAAP Income Guidance - Quick FactsBioMarin Increases 2017 Non-GAAP Income Guidance - Quick Facts
www.nasdaq.com - October 26 at 9:46 PM
EARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q3 Earnings Report
www.rttnews.com - October 26 at 9:46 PM
BioMarin reports 3Q lossBioMarin reports 3Q loss
finance.yahoo.com - October 26 at 9:46 PM
BioMarin Pharmaceutical Inc. (BMRN) Releases Quarterly  Earnings Results, Beats Estimates By $0.28 EPSBioMarin Pharmaceutical Inc. (BMRN) Releases Quarterly Earnings Results, Beats Estimates By $0.28 EPS
www.americanbankingnews.com - October 26 at 6:02 PM
BioMarin Pharma (BMRN) FDA Granted Breakthrough Therapy Designation for Valoctocogene Roxaparvovec for ... - StreetInsider.comBioMarin Pharma (BMRN) FDA Granted Breakthrough Therapy Designation for Valoctocogene Roxaparvovec for ... - StreetInsider.com
www.streetinsider.com - October 26 at 4:44 PM
BioMarin Announces Third Quarter 2017 Financial ResultsBioMarin Announces Third Quarter 2017 Financial Results
finance.yahoo.com - October 26 at 4:44 PM
Head-To-Head Survey: BioMarin Pharmaceutical (BMRN) vs. The CompetitionHead-To-Head Survey: BioMarin Pharmaceutical (BMRN) vs. The Competition
www.americanbankingnews.com - October 26 at 1:38 PM
BioMarin Reports Breakthrough Therapy Designation For Valoctocogene RoxaparvovecBioMarin Reports Breakthrough Therapy Designation For Valoctocogene Roxaparvovec
www.nasdaq.com - October 26 at 9:05 AM
BioMarin Pharma (BMRN) FDA Granted Breakthrough Therapy Designation for Valoctocogene Roxaparvovec for Hemophilia ABioMarin Pharma (BMRN) FDA Granted Breakthrough Therapy Designation for Valoctocogene Roxaparvovec for Hemophilia A
www.streetinsider.com - October 26 at 9:05 AM
FDA Grants Breakthrough Therapy Designation for BioMarins Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia AFDA Grants Breakthrough Therapy Designation for BioMarin's Valoctocogene Roxaparvovec (formerly BMN 270), an Investigational Gene Therapy for Hemophilia A
finance.yahoo.com - October 26 at 9:05 AM
BioMarin: No Short-Term Catalysts, Slowing Revenue GrowthBioMarin: No Short-Term Catalysts, Slowing Revenue Growth
seekingalpha.com - October 25 at 6:06 PM
BioMarin Pharmaceutical (BMRN) vs. Its Rivals Financial ContrastBioMarin Pharmaceutical (BMRN) vs. Its Rivals Financial Contrast
www.americanbankingnews.com - October 25 at 7:14 AM
What's in Store for BioMarin (BMRN) This Earnings Season?What's in Store for BioMarin (BMRN) This Earnings Season?
finance.yahoo.com - October 24 at 3:42 AM
Whats in Store for BioMarin (BMRN) This Earnings Season? - NasdaqWhat's in Store for BioMarin (BMRN) This Earnings Season? - Nasdaq
www.nasdaq.com - October 23 at 5:32 PM
Gabelli Comments on BioMarin Pharmaceutical Inc.s FY2019 Earnings (BMRN)Gabelli Comments on BioMarin Pharmaceutical Inc.'s FY2019 Earnings (BMRN)
www.americanbankingnews.com - October 23 at 9:02 AM
Leerink Swann Equities Analysts Decrease Earnings Estimates for BioMarin Pharmaceutical Inc. (BMRN)Leerink Swann Equities Analysts Decrease Earnings Estimates for BioMarin Pharmaceutical Inc. (BMRN)
www.americanbankingnews.com - October 23 at 2:18 AM
Brokers Issue Forecasts for BioMarin Pharmaceutical Inc.s Q3 2017 Earnings (BMRN)Brokers Issue Forecasts for BioMarin Pharmaceutical Inc.'s Q3 2017 Earnings (BMRN)
www.americanbankingnews.com - October 23 at 2:18 AM
BioMarin Pharmaceutical Inc. (BMRN) PT Set at $115.00 by SunTrust Banks, Inc.BioMarin Pharmaceutical Inc. (BMRN) PT Set at $115.00 by SunTrust Banks, Inc.
www.americanbankingnews.com - October 21 at 4:44 PM
BioMarin Pharmaceutical is Now Oversold (BMRN)BioMarin Pharmaceutical is Now Oversold (BMRN)
www.forbes.com - October 20 at 6:24 PM
Leerink Swann Comments on BioMarin Pharmaceutical Inc.s FY2018 Earnings (BMRN)Leerink Swann Comments on BioMarin Pharmaceutical Inc.'s FY2018 Earnings (BMRN)
www.americanbankingnews.com - October 20 at 5:28 PM
BioMarin Pharmaceutical Inc. (BMRN) Receives "Buy" Rating from BMO Capital MarketsBioMarin Pharmaceutical Inc. (BMRN) Receives "Buy" Rating from BMO Capital Markets
www.americanbankingnews.com - October 20 at 5:16 PM
BioMarin Pharmaceutical (BMRN) and Alexion Pharmaceuticals (ALXN) Head to Head ReviewBioMarin Pharmaceutical (BMRN) and Alexion Pharmaceuticals (ALXN) Head to Head Review
www.americanbankingnews.com - October 20 at 6:28 AM
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : October 19, 2017BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : October 19, 2017
finance.yahoo.com - October 19 at 5:14 PM
BioMarin Pharmaceutical Inc. (BMRN) Price Target Raised to $124.00 at Credit Suisse GroupBioMarin Pharmaceutical Inc. (BMRN) Price Target Raised to $124.00 at Credit Suisse Group
www.americanbankingnews.com - October 19 at 11:44 AM
BioMarin Pharmaceutical Inc. (BMRN) Rating Reiterated by Leerink SwannBioMarin Pharmaceutical Inc. (BMRN) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - October 19 at 11:44 AM
BioMarin Pharmaceutical Inc. (BMRN) to Release Earnings on ThursdayBioMarin Pharmaceutical Inc. (BMRN) to Release Earnings on Thursday
www.americanbankingnews.com - October 19 at 2:32 AM
Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6624.22. - NasdaqMarket Close Report: Historical high reached as NASDAQ Composite Index closes at 6624.22. - Nasdaq
www.nasdaq.com - October 18 at 10:58 PM
BioMarin Pharma (BMRN) Provides Highlights from R&D Day, Reaffirms Guidance - StreetInsider.comBioMarin Pharma (BMRN) Provides Highlights from R&D Day, Reaffirms Guidance - StreetInsider.com
www.streetinsider.com - October 18 at 10:58 PM
BioMarin is 'close as can get' to a hemophilia cure, CEO ...BioMarin is 'close as can get' to a hemophilia cure, CEO ...
finance.yahoo.com - October 18 at 10:58 PM

Social Media

Financials

Chart

BioMarin Pharmaceutical (NASDAQ BMRN) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.